Department of Gastrointestinal Surgery, The First Affiliated Hospital, Yijishan Hospital of Wannan Medical College, Wuhu, China.
Department of Hepatobiliary Surgery, The First Affiliated Hospital, Yijishan Hospital of Wannan Medical College, Wuhu, China.
Clin Transl Oncol. 2024 Oct;26(10):2718-2737. doi: 10.1007/s12094-024-03495-4. Epub 2024 May 4.
Cuproptosis, as a unique modality of regulated cell death, requires the involvement of ubiquitin-binding enzyme UBE2D2. However, the prognostic and immunotherapeutic values of UBE2D2 in pan-cancer remain largely unknown.
Using UCSC Xena, TIMER, Clinical Proteomic Tumor Analysis Consortium (CPTAC), and Human Protein Atlas (HPA) databases, we aimed to explore the differential expression pattern of UBE2D2 across multiple cancer types and to evaluate its association with patient prognosis, clinical features, and genetic variations. The association between UBE2D2 and immunotherapy response was assessed by gene set enrichment analysis, tumor microenvironment, immune gene co-expression and drug half maximal inhibitory concentration (IC50) analysis.
The mRNA and protein levels of UBE2D2 were markedly elevated in most cancer types, and UBE2D2 exhibited prognostic significance in liver hepatocellular carcinoma (LIHC), kidney chromophobe (KICH), uveal melanomas (UVM), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), and kidney renal papillary cell carcinoma (KIRP). UBE2D2 expression was correlated with clinical features, tumor mutation burden, microsatellite instability, and anti-tumor drug resistance in several tumor types. Gene enrichment analysis showed that UBE2D2 was significantly associated with immune-related pathways. The expression level of UBE2D2 was correlated with immune cell infiltration, including CD4 + T cells、Macrophages M2、CD8 + T cells in pan-cancer. PDCD1, CD274 and CTLA4 expression levels were positively correlated with UBE2D2 level in multiple cancers.
We comprehensively investigated the potential value of UBE2D2 as a prognostic and immunotherapeutic predictor for pan-cancer, providing a novel insight for cancer immunotherapy.
铜死亡作为一种独特的细胞死亡方式，需要泛素结合酶 UBE2D2 的参与。然而，UBE2D2 在多种癌症中的预后和免疫治疗价值在很大程度上仍然未知。
使用 UCSC Xena、TIMER、临床蛋白质组肿瘤分析联盟 (CPTAC) 和人类蛋白质图谱 (HPA) 数据库，我们旨在探索 UBE2D2 在多种癌症类型中的差异表达模式，并评估其与患者预后、临床特征和遗传变异的关系。通过基因集富集分析、肿瘤微环境、免疫基因共表达和药物半数最大抑制浓度 (IC50) 分析评估 UBE2D2 与免疫治疗反应的关系。
UBE2D2 的 mRNA 和蛋白水平在大多数癌症类型中显著升高，UBE2D2 在肝癌 (LIHC)、肾嫌色细胞癌 (KICH)、葡萄膜黑色素瘤 (UVM)、宫颈鳞状细胞癌和宫颈内膜腺癌 (CESC) 和肾肾乳头细胞癌 (KIRP) 中具有预后意义。UBE2D2 的表达与几种肿瘤类型的临床特征、肿瘤突变负担、微卫星不稳定性和抗肿瘤药物耐药性相关。基因富集分析表明，UBE2D2 与免疫相关途径显著相关。UBE2D2 的表达水平与免疫细胞浸润相关，包括泛癌症中的 CD4+T 细胞、M2 巨噬细胞、CD8+T 细胞。在多种癌症中，PDCD1、CD274 和 CTLA4 的表达水平与 UBE2D2 水平呈正相关。
我们全面研究了 UBE2D2 作为泛癌症预后和免疫治疗预测因子的潜在价值，为癌症免疫治疗提供了新的见解。
